Agreement - November 30, 2020
Alvotech enters biosimilar partnership in China
Alvotech and Alvotech & CCHT Biopharmaceutical, which is the China joint venture company of Alvotech hf. and Changchun High & New Technology Industries (Group) Inc., have partnered with Yangtze River Pharmaceutical Group to form an exclusive strategic partnership for the commercialization of eight biosimilar medicines in China. The initial pipeline contains biosimilar candidates for treatment […]
Agreement - November 23, 2020
Bio-Me and Siolta Therapeutics to collaborate
Microbiome Dx company Bio-Me and Siolta Therapeutics have entered into a collaboration and marketing agreement. Under the agreement, Siolta will provide both samples and insights into key criteria for Bio-Me to develop a rapid, detailed and comprehensive diagnostic test for infants at risk of developing allergy and asthma, they state. The test will be offered […]
Agreement - October 30, 2020
AstraZeneca’s Atacand to be divested to Cheplapharm in more than 70 countries
AstraZeneca has agreed to sell the commercial rights to Atacand (candesartan cilexetil) and AtacandPlus (a fixed-dose combination of candesartan cilexetil and hydrochlorothiazide) in around 70 countries globally to Cheplapharm. Atacand is aprescription medicine approved for the treatment of heart failure (HF) and hypertension. Atacand Plus is approved for the treatment of hypertension. “This agreement forms part of our […]
Agreement - October 28, 2020
BioInvent enters licensing agreement for Greater China region
BioInvent International and CASI Pharmaceuticals, a U.S. biopharmaceutical company with an established clinical development and commercial infrastructure in China, have entered into an exclusive licensing agreement for the development and commercialization of novel anti-FcγRIIB antibody, BI-1206, in mainland China, Taiwan, Hong Kong and Macau. “BioInvent will receive a $5 million upfront payment and is eligible […]
Agreement - October 15, 2020
ArcticZymes in agreement with Simcere Diagnostics
Tromsø based ArcticZymes AS, a subsidiary of ArcticZymes Technologies, has entered into a supply and distribution agreement with precision medicine company Jiangsu Simcere Diagnostics, Nanjing, China. “This is just the beginning of a long-term relationship together where ArcticZymes’ novel enzyme technologies and scientific competence will aid Simcere Diagnostics in marketing best in class sequencing technologies. […]
Agreement - October 13, 2020
Scandinavian Biopharma enters into agreement with USAMRAA
Scandinavian Biopharma has entered into an agreement with the United States Army Medical Research Acquisition Activity (USAMRAA) to support the production and development of the vaccine, with the long-term goal of preventing bacterial diarrhoea in war fighters. In April this year, SBH announced the preliminary findings from a Phase 2b study of the oral vaccine […]
